Faron Pharmaceuticals Oy (LON:FARN) Shares Up 1.1% – Still a Buy?

Faron Pharmaceuticals Oy (LON:FARN) traded up 1.1% during mid-day trading on Thursday . The stock traded as high as GBX 54 and last traded at GBX 47. 435,065 shares were traded during trading, an increase of 120% from the average session volume of 197,504 shares. The stock had previously closed at GBX 46.50.

Faron Pharmaceuticals Oy Price Performance

The company has a market cap of £53.78 million, a PE ratio of -1.74 and a beta of 0.36. The firm’s 50-day moving average is GBX 158.10 and its 200-day moving average is GBX 180.79. The company has a quick ratio of 1.09, a current ratio of 1.45 and a debt-to-equity ratio of 922.55.

Insider Buying and Selling at Faron Pharmaceuticals Oy

In other Faron Pharmaceuticals Oy news, insider Jurriaan Dekkers sold 4,000 shares of the firm’s stock in a transaction dated Monday, January 12th. The stock was sold at an average price of GBX 182, for a total value of £7,280. 4.05% of the stock is owned by insiders.

Faron Pharmaceuticals Oy Company Profile

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.